Oral Hypoglycemic Agent continuation versus Interruption in type 2 Diabetes Patients Undergoing Ambulatory Surgery.
Patients with established diagnosis of type 2 DM who are on OHA monotherapy or combination OHA and are scheduled to undergo ambulatory surgery will be identified. Informed consent will be obtained from 100 consecutive study participants.
Patients, will be randomized into 2 groups – OHA treatment on day of surgery (H1 group, n= 50) and patients not receiving OHA on day of surgery (H0, n=50) as prescribed by their provider.
All patients will be processed through the anesthesia preoperative clinic and instructions regarding preoperative medication handling will be provided to study participants by the investigator.
On the morning of the surgical procedure, the investigator will verify that medication administration instructions provided to the study participant was adhered to.
The patient will be checked-in into the ambulatory surgery suite and usual surgical preparatory procedures followed. Pre-anesthesia capillary blood glucose measurement will be performed and recorded in the presurgical area.
Anesthesia will be induced and maintained in the usual fashion. Intraoperative capillary blood glucose levels will be checked and recorded hourly until the end of surgery.
The investigator will ensure that glucose containing maintenance intravascular fluids are avoided throughout the anesthesia and surgery unless specifically indicated for treatment.
All patients will be awakened from anesthesia and extubated at the end of surgery and transferred to the post anesthesia recovery (PAR) area as appropriate. Capillary blood glucose will be measured after arrival in the PAR.
Criteria for Inclusion of Subjects:
Subjects will consist of men and women 18-80 years old with established diagnosis of type 2 diabetes mellitus undergoing ambulatory surgery.
Criteria for Exclusion of Subjects:
Subjects who are on treatment with insulin as monotherapy or in combination with OHA and amp;apos;s such as Thiazolidinediones-Repaglimide (Prandin), Rosiglitazone (Avandia), Pioglitazone (Actos).
Subject with renal Insufficiency and Serum Creatinine and amp;gt; 2mg/dl and subjects with decompensated congestive heart failure will be excluded from the study.
1. Men and women 18-80 years old
2. Established diagnosis of type 2 diabetes mellitus
3. Undergoing ambulatory surgery.
4. Patients must be on OHA monotherapy for diabetes or combination OHA therapy